Remote Monitoring in Young Adults With Inflammatory Joint Disease
A legfontosabb adatok
- Ki végzi
- Diakonhjemmet Hospital
- Hol
- Norvégia1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 148 fő, tervezett
- Kezdés
- 2026. dec.
- Várható befejezés
- 2029. dec.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Remote digital follow-up
- Conventional hospital-based follow-up
- A regiszteradat frissítve
- 2026. november 16.
Ki vehet részt
- Életkor
- 18 év – 30 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 17 feltétel megnézéseKevesebb
Ki vehet részt
- Biological male or female aged 18-30 years at the time of informed consent
- Clinical diagnosis of JIA, RA, SpA, or PsA
- Stable DMARD treatment for ≥ 6 months; no initiation, discontinuation, or major dose escalation of a DMARD during the preceding 6 months. Temporary treatment interruptions and minor dose adjustments may be permitted
- Inactive disease or low disease activity at inclusion, according to diagnosis specific instrument thresholds (JADAS27≤2.7, DAS28≤ 3.2, ASDAS< 2.1, DAPSA≤14)
- Ability to understand Norwegian
- Capable of providing written informed consent
- Access to a smartphone or tablet compatible with installation of the Dignio application
Ki nem vehet részt
- Major co-morbidities, such as severe malignancies, severe diabetes mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease (NYHA class III or IV), severe respiratory diseases, and/or cirrhosis
- Indications of active tuberculosis (TB)
- Stills disease (systemic JIA)
- Severe psychiatric or mental disorders; current alcohol or other substance abuse; substantial language barriers; or any condition or circumstance that, in the investigator's judgment, would make adherence to the study protocol impossible
- Abnormal renal function, defined as serum creatinine >142 µmol/L in female and >168 µmol/L in male, or glomerular filtration rate (GFR) <40 mL/min/1.73 m2
- Abnormal liver function (defined as Alanine Transaminase (ALT) >3x upper normal limit), active or recent hepatitis
- Pregnant and/or breastfeeding
- Currently enrolled in a different RCT
- Leukopenia and/or thrombocytopenia
- Planned pregnancy during the study period
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 30 év között vagy?
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this clinical trial is to learn whether remote follow-up can work as well as regular in-person follow-up at the hospital for young adults with inflammatory joint diseases who have low disease activity. The study includes people aged 18 to 30 years with juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, or spondyloarthritis.
A teljes eredeti leírásKevesebb
The main questions it aims to answer are:
* Is remote follow-up non-inferior (not worse than) to regular in-person follow-up at the hospital in keeping participants' disease under good control over 24 months? * Is remote follow-up non-inferior to regular in-person follow-up when it comes to disease flare-ups, use of healthcare services, medication use, satisfaction with care, and safety? Researchers will compare a remote follow-up program, with fewer routine outpatient visits, to regular in-person follow-up to see whether disease control after 24 month is non-inferior (not worse)
Participants will:
* Be randomly assigned to either remote digital follow-up or regular in-person follow-up at the hospital . * Complete questionnaires about their symptoms, health, and treatment during the study. * Attend appointments with a rheumatologist at the start of the study and at study end at 24 months. * If assigned to remote follow-up, complete questionnaires every 3 months using a smartphone or tablet application and communicate with a study nurse when needed through secure messaging in the remote monitoring software platform. * If assigned to regular in-person follow-up, attend routine appointments at the rheumatology clinic according to usual practice.
This study aims to determine whether remote follow-up can provide a safe and effective alternative to regular in-person follow-up for young adults with inflammatory joint diseases who have low disease activity .
A vizsgálat 2 csoportja
- Remote digital follow-upA vizsgált kezelés
Structured remote follow-up for 24 months using the MyDignio digital platform, with electronic triage questionnaires every three months, nurse review of alerts and messages, and scheduled consultations at baseline, 12 and 24 months. Participants continue their prescribed antirheumatic treatment.
- Conventional hospital-based follow-upMár használt kezelés, összehasonlításként
Standard rheumatology outpatient follow-up for 24 months, with scheduled rheumatologist and nurse contacts at baseline, 6, 12, 18 and 24 months. Participants continue their prescribed antirheumatic treatment
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Remote Monitoring and Personalized Patient Pathways in Young Adults With Inflammatory Joint Disease (ReMonit Young)
- Kérdések a feltételekről
- Forrás: NCT07937475: ki vehet részt
- A regiszteradat frissítve
- 2026. november 16.